
DB-OTO Study Published in New England Journal of Medicine Demonstrates Significant, Lasting Gains in Hearing and Speech for Children with Profound Genetic Hearing Loss
Regeneron Presents Latest DB-OTO Data Showing Dramatic and Sustained Hearing and Speech Improvements in Children with Profound Genetic Hearing Loss Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updated data for its investigational gene therapy DB-OTO for profound genetic hearing loss…











